Therapeutic siRNA for drug-resistant HER2-positive breast cancer.

Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol; Castro, David J; Morry, Jingga; Reda, Moataz M; Gray, Joe W; Yantasee, Wassana

Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol; Castro, David J; Morry, Jingga; Reda, Moataz M; Gray, Joe W; Yantasee, Wassana.

Affiliation

Gu S; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA.
Hu Z; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA.
Ngamcherdtrakul W; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA.
Castro DJ; PDX Pharmaceuticals, LLC, Portland, Oregon, 97239, USA.
Morry J; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA.
Reda MM; PDX Pharmaceuticals, LLC, Portland, Oregon, 97239, USA.
Gray JW; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA.
Yantasee W; Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA.

Oncotarget ; 7(12): 14727-41, 2016 Mar 22.

Article de En | MEDLINE | ID: mdl-26894975

Sujet(s)
Mots clés

HER2; breast cancer; nanoparticles; siRNA; trastuzumab resistance

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Récepteur ErbB-2 / Résistance aux médicaments antinéoplasiques / Petit ARN interférent / Antinéoplasiques Limites: Animals / Female / Humans Langue: En Journal: Oncotarget Année: 2016 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google